Highest-materiality recent filing
Precigen Q1: PAPZIMEOS nets $21.6M revenue; loss narrows to $7.9M
Net product revenue from PAPZIMEOS was $21.6M in Q1 2026, first full quarter post-FDA approval.
Precigen posts FY2025 net loss of $1.37/sh; PAPZIMEOS Q4 revenue $3.4M, launch momentum strong
PAPZIMEOS generated $3.4M in net product revenue in Q4 2025, first partial quarter of US commercial sales.
Precigen Reports Q3 2025 Financial Results; PAPZIMEOS Full FDA Approval in August
PAPZIMEOS (zopapogene imadenovec-drba) received full FDA approval in August 2025 for adults with RRP.
Precigen: $79M Preferred Stock converted into 54.9M common shares
Holders converted 79,000 shares of 8.00% Series A Convertible Preferred Stock (stated value $79M) into 54,937,411 common shares.
Precigen secures up to $125M non-dilutive senior secured loan financing from Pharmakon
$100M funded at close; $25M delayed draw available through June 2027; matures Sept 2030.
Precigen enters into commercial supply agreement with Catalent for PAPIZEMOS manufacturing
Agreement dated August 13, 2025 with Catalent Maryland for fill/finish services for gene therapy PAPIZEMOS (PRGN-2012).
Precigen announces FDA approval of PAPZIMEOS (no further details)
US FDA approval of PAPZIMEOS announced via slide deck at August 18, 2025 investor webcast.
Precigen shareholders approve 300M share increase, re-elect directors, and expand equity plans
Increased authorized common shares by 300 million (223.2M votes for).
Precigen Q1 net loss $54.2M; PRGN-2012 BLA under FDA priority review with PDUFA Aug 27
Net loss of $54.2M ($0.18/share) vs $23.7M ($0.10) YoY; includes $32.5M non-cash warrant liability fair value change.
Precigen reports FY2024 net loss of $126M; FDA priority review for PRGN-2012 BLA
FDA accepted BLA for PRGN-2012 with priority review; PDUFA target date Aug 27, 2025.
Precigen regains Nasdaq bid price compliance, delisting risk resolved
Nasdaq notified Precigen on Jan 16, 2025 that it regained compliance with the $1.00 minimum bid price rule.
Precigen completes BLA submission for PRGN-2012 and raises $79M in private placement
Submitted BLA to FDA for PRGN-2012 (RRP), requesting priority review; 60-day review period to determine acceptance.
Precigen sells FCX-007 assets for $8.5M cash, exits Castle Creek collaboration
Asset Acquisition Agreement with Innovator 21 (Paragon affiliate) closed Dec 24, 2024 for $8.5M cash.
Precigen Q3 net loss widens to $24M; on track for Q4 PRGN-2012 BLA submission
Net loss of $24.0M ($0.09/sh) vs $19.8M loss YoY; nine-month loss $106.5M ($0.41/sh).
Precigen receives Nasdaq bid price deficiency notice; has until Apr 30, 2025 to regain compliance
Stock closed below $1 for 30 consecutive business days; compliance deadline April 30, 2025.
Precigen terminates Alaunos license agreement, regains all rights
Terminated Amended and Restated License Agreement with Alaunos effective Oct 4, 2024.
Precigen SVP of Intellectual Property Affairs Jeffrey Perez to depart Nov 1, 2024
Jeffrey Perez, SVP of Intellectual Property Affairs, will separate from Precigen effective November 1, 2024.
Precigen grants PSUs tied to PRGN-2012 BLA milestones to named execs
Target PSUs granted: CEO Helen Sabzevari 1,650,000; CFO Harry Thomasian 250,000; COO Rutul Shah 250,000; CLO Donald Lehr 108,000.
Precigen Q2 net loss widens to $58.8M; pivots to PRGN-2012 with BLA submission planned H2 2024
Q2 2024 net loss of $58.8M ($0.23/share) vs $20.3M loss a year ago; includes impairment charge of $32.9M.
Precigen raises ~$31.4M net in underwritten public offering of 35.3M shares at $0.85
Precigen entered into underwriting agreement with Stifel for offering of 35,294,118 shares at $0.85/share.
Precigen reports $19.5M cash, $32.9M impairment, $30M offering, >20% workforce cut
Preliminary cash $19.5M at June 30, 2024; non-cash impairment charges ~$32.9M and severance ~$3.0M in Q2/Q3.
Precigen elects Nancy Howell Agee to board; shareholders approve 2M share increase in incentive plan
Dean Mitchell's term ended July 5, 2024; he did not stand for re-election, no disagreement cited.
Precigen Q1 net loss $23.7M, revenue down 43%; PRGN-2012 BLA submission on track for H2 2024
Net loss $23.7M ($0.10 EPS) vs $22.7M; total revenue down 43% YoY to approx. $1.06M.
Precigen reports FY2023 loss of $95.9M; plans BLA submission for PRGN-2012 in H2 2024
FY2023 revenue $6.2M, down 77% YoY; net loss $95.9M ($0.39 loss per share).
On September 23, 2024, Precigen, Inc. (the “Company”) announced the separation from employment of Jeffrey Perez, Senior Vice President, Intellectual Property Affairs, effective November 1, 2024.
As described under Item 5.07 below, at the 2024 Annual Meeting, Nancy Howell Agee was elected to the Board, effective as of July 5, 2024.
As previously disclosed in the Proxy Statement, Dean Mitchell did not stand for re-election at 2024 Annual Meeting. Accordingly, Mr. Mitchell’s term on the Board ended effective as of July 5, 2024.
Max materiality 0.90 · Median 0.72 · Most common event earnings